Guests/Speakers
Lysa Buonanno, Voices of Hope Speakers Bureau, Patient Advocate
Dr. Alice Berger, Associate Professor, Fred Hutch Cancer Center, Seattle, WA
Understanding EGFR Mutations: Knowledge Is Power
If you or someone you love has been diagnosed with EGFR-positive lung cancer, one of the first questions you may ask is: “What does this mean for my family?” You are not alone. Patient advocate Lysa Buonanno sits down with Dr. Alice Berger, a lung cancer researcher at Fred Hutch Cancer Center, to unpack what EGFR mutations really are — and what they mean for patients and their loved ones.
What Is an EGFR Mutation?
EGFR stands for epidermal growth factor receptor. In lung cancer, an EGFR mutation is a change in the EGFR gene that helps drive the growth of cancer cells. Dr. Berger explains that in almost all cases, EGFR mutations are acquired — meaning they develop in lung cells at some point during a person’s life. You are not born with them. In very rare cases, a person may inherit a variant in EGFR that raises their risk, but this is uncommon.
This is reassuring news for many patients and parents. As Lysa shares,
“When I was diagnosed with a lung cancer that has a biomarker, my first thought was, ‘Is this something I could pass down to my kids?'”
Dr. Berger confirms that for EGFR mutations — and other common lung cancer biomarkers like ALK and ROS1 — the answer is almost always no. These are somatic mutations, meaning they occur by chance or through exposure during life and are not passed down through families.
Should Your Family Be Tested?
While inherited EGFR mutations are rare, Dr. Berger encourages patients to have an open conversation with their doctor. If you have had biomarker testing to identify your EGFR mutation, it is worth asking whether the test can tell if the mutation was acquired or present from birth. A first-degree relative — such as a parent or sibling — who has had lung cancer does increase your overall risk, and your primary care provider may recommend additional screening.
Other inherited gene changes, such as mutations in P53 (Li-Fraumeni syndrome), ATM, CDKN2A, and even BRCA (known for breast and ovarian cancer risk), can also raise the risk of lung cancer. If there is a history of lung cancer or other cancers in your family, asking your doctor about genetic testing is a proactive step you can take.
Risk Factors Beyond Genetics
Dr. Berger reminds listeners that lung cancer risk is shaped by more than genetics. Smoking remains a leading risk factor, but radon exposure, air pollution, and family history all play a role. Understanding your full picture of risk helps you and your care team make informed decisions about screening and prevention.
Targeted Treatments Offer Real Hope
For patients with EGFR-positive lung cancer, targeted therapies have transformed the treatment landscape. The current standard of care is osimertinib (Tagrisso), a type of drug called a tyrosine kinase inhibitor (TKI). TKIs work by binding to the mutant form of EGFR and blocking its ability to fuel cancer growth. For most patients, this leads to tumor shrinkage and meaningful survival benefits.
And the progress does not stop there. Dr. Berger highlights several exciting new treatment options that have received FDA accelerated approvals, including:
- TROP2 antibody drug conjugates — a new class of therapy showing promising results for patients whose cancer has progressed on osimertinib.
- New EGFR inhibitors for exon 20 insertion mutations — a type of EGFR mutation that is less responsive to osimertinib, now with its own approved targeted therapy.
The Future of EGFR Research
Researchers are also working to understand why EGFR-positive lung cancer occurs at higher rates in certain populations, including people of Asian ancestry. This points to additional inherited risk factors that science has not yet identified. Dr. Berger describes this as “a big area of active research” that could open new doors for prevention and early detection.
This episode is a powerful reminder that knowledge, advocacy, and the right care team can make all the difference. If you have been diagnosed with EGFR-positive lung cancer, ask your doctor about comprehensive biomarker testing, explore your targeted therapy options, and know that research is advancing every day on your behalf.
